Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Sept 2021

Eastman Alice C, Pace Rhonda G, Dang Hong, Aksit Melis Atalar, Vecchio-Pagán Briana, Lam Anh-Thu N, O'Neal Wanda K, Blackman Scott M, Knowles Michael R, Cutting Garry R

Abstract excerpt

BACKGROUND: The CFTR modulator ivacaftor has been variably effective in treating individuals with cystic fibrosis (CF) who harbor CFTR gating variants such as G551D, as well as other classes of CFTR variants when used with other modulators. Because CFTR genotype does not fully explain this variability, defining genetic modifiers of response to modulator therapy is of particular interest to the field of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Antiporters

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Quinolones

Share to Respiratory Function Tests

Share to Severity of Illness Index

Share to Sulfate Transporters

Source

Open in PubMed Open full text

Identifiers

PMID: 33674211
DOI: 10.1016/j.jcf.2021.02.007
PMCID: PMC8410892

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR.PMID 33674211Read ↗

Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung diseaseSemantic proximity Read ↗

Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR GenotypeSemantic proximity Read ↗

Complete CFTR gene sequencing in 5,058 individuals with cystic fibrosis informs variant-specific treatment.Semantic proximity Read ↗

Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.Semantic proximity Read ↗

Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.Semantic proximity Read ↗

CFTR bearing variant p.Phe312del exhibits function inconsistent with phenotype and negligible response to ivacaftor.Semantic proximity Read ↗

Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosisSemantic proximity Read ↗

The Solute Carrier Family 26 Member 9 Is a Modifier of the Rapidly Progressing Cystic Fibrosis Associated with F508del CFTR MutationsSemantic proximity Read ↗

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.Semantic proximity Read ↗

The solute carrier family 26 member 9 modifies rapidly progressing cystic fibrosis associated with homozygous F508del CFTR mutation.Semantic proximity Read ↗

Missense variants in CFTR nucleotide-binding domains predict quantitative phenotypes associated with cystic fibrosis disease severity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.